Data Year:

For its 2025 fiscal year, ABBOTT LABORATORIES, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Hubert L. Allen
Former Executive Vice President, General Counsel and Secretary
Total Compensation $5,815,744 View details Pay Rank By Title In MFG Durable industry #8 View more
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Total Compensation $22,004,356 View details Pay Rank By Title In MFG Durable industry #46 View more
Daniel G. Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
Total Compensation $6,002,767 View details Pay Rank By Title In MFG Durable industry #41 View more
Lisa D. Earnhardt
Executive Vice President and Group President, Medical Devices
Total Compensation $7,474,937 View details Pay Rank By Title In MFG Durable industry #26 View more
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer
Total Compensation $8,196,334 View details Pay Rank By Title In MFG Durable industry #40 View more
Christopher J. Scoggins
Executive Vice President, Diabetes Care
Total Compensation $5,388,491 View details Pay Rank By Title In MFG Durable industry #45 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ABBOTT LABORATORIES as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ABBOTT LABORATORIES income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ABBOTT LABORATORIES annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Hubert L. Allen
Former Executive Vice President, General Counsel and Secretary
Total Cash $971,519 Equity $4,191,001 Other $653,224 $5,815,744
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Total Cash $3,468,750 Equity $17,575,808 Other $959,798 $22,004,356
Daniel G. Salvadori
Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
Total Cash $1,312,431 Equity $4,477,835 Other $212,501 $6,002,767
Lisa D. Earnhardt
Executive Vice President and Group President, Medical Devices
Total Cash $2,207,631 Equity $5,088,353 Other $178,953 $7,474,937
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer
Total Cash $2,029,631 Equity $6,092,285 Other $74,418 $8,196,334
Christopher J. Scoggins
Executive Vice President, Diabetes Care
Total Cash $1,954,802 Equity $3,325,246 Other $108,443 $5,388,491
For its 2025 fiscal year, ABBOTT LABORATORIES, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Robert B. Ford CEO Pay $24,198,660 Median Employee Pay $145,528 CEO Pay Ratio 166:1
For its 2025 fiscal year, ABBOTT LABORATORIES, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
C. Babineaux-Fontenot Total Cash $366,906
D. J. Starks Total Cash $360,906
D. W. McDew Total Cash $335,906
J. G. Stratton Total Cash $388,573
M. A. Kumbier Total Cash $341,906
M. F. Roman Total Cash $357,573
M. G. O'Grady Total Cash $335,906
N. McKinstry Total Cash $406,665
P. Gonzalez Total Cash $341,906
R. J. Alpern Total Cash $473,491
S. E. Blount Total Cash $374,335
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.